Literature DB >> 16467721

Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis.

Wei-Hsiung Huang1, Pei-Kai Hung.   

Abstract

OBJECTIVE/HYPOTHESIS: Methicillin-resistant Staphylococcus aureus (MRSA) has recently become a serious problem in various fields of medicine. However, it has rarely been studied in acute rhinosinusitis. The aim of this study was to identify the clinical manifestations and treatment outcome of community-acquired methicillin-resistant S. aureus in acute rhinosinusitis. STUDY
DESIGN: This was a prospectively collected case series.
METHODS: Since 2000, we have launched a prospective long-term study for bacteriology, drug susceptibility, and their changing trend in acute rhinosinusitis. Patients with the diagnosis of acute rhinosinusitis were enrolled from October 2000 through March 2003. Their middle meatus discharge was taken for aerobic culture. Antibiotic sensitivity test was performed for each isolate.
RESULTS: A total of 601 patients with the diagnosis of acute rhinosinusitis were included in this study. MRSA was isolated in 16 specimens. Its prevalence rate in acute rhinosinusitis was 2.7% (16 of 601). Multiple pathogens were more frequently found in children with MRSA infection. Five of seven adults had previous nasal procedures. Eight of nine children had a history of antibiotic use. Except for two patients without follow up, the remaining 14 patients resolved after receiving oral antibiotics according to culture results.
CONCLUSIONS: The incidence of MRSA infection in acute rhinosinusitis was 2.7% in our study. The most important risk factor was nasal surgeries in adults and previous antibiotic use in children. The treatment outcome of community-acquired MRSA was excellent with oral antibiotics.

Entities:  

Mesh:

Year:  2006        PMID: 16467721     DOI: 10.1097/01.mlg.0000197316.36698.c4

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  8 in total

Review 1.  Mechanisms of Blood Brain Barrier Disruption by Different Types of Bacteria, and Bacterial-Host Interactions Facilitate the Bacterial Pathogen Invading the Brain.

Authors:  Mazen M Jamil Al-Obaidi; Mohd Nasir Mohd Desa
Journal:  Cell Mol Neurobiol       Date:  2018-08-16       Impact factor: 5.046

2.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

Review 3.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

4.  Trends in incidence and susceptibility among methicillin-resistant Staphylococcus aureus isolated from intranasal cultures associated with rhinosinusitis.

Authors:  Valin Rujanavej; Ethan Soudry; Niaz Banaei; Ellen Jo Baron; Peter H Hwang; Jayakar V Nayak
Journal:  Am J Rhinol Allergy       Date:  2013 Mar-Apr       Impact factor: 2.467

5.  Rising Methicillin-Resistant Staphylococcus aureus Infections in Ear, Nose, and Throat Diseases.

Authors:  Sangeetha Thirumazhisi Sachithanandam
Journal:  Case Rep Otolaryngol       Date:  2014-11-06

6.  Acute rhinosinusitis among pediatric patients with allergic rhinitis: A nationwide, population-based cohort study.

Authors:  Shi-Wei Lin; Sheng-Kai Wang; Ming-Chi Lu; Chun-Lung Wang; Malcolm Koo
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

7.  Acute MRSA sinusitis with intracranial extension and marginal vancomycin susceptibility.

Authors:  Parvathi S Kumar; Kenji M Cunnion
Journal:  Case Rep Pediatr       Date:  2013-09-11

Review 8.  Microbiologic investigations for head and neck infections.

Authors:  Diane L Roscoe; Linda Hoang
Journal:  Infect Dis Clin North Am       Date:  2007-06       Impact factor: 5.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.